{"id":"W4414975794","doi":"10.3324/haematol.2025.288780","title":"Real-world safety and tolerability of rapid infusion obinutuzumab in chronic lymphocytic leukemia, small lymphocytic lymphoma and non-Hodgkin lymphoma: a provincial review","year":2025,"lang":"en","type":"review","venue":"Haematologica","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Manitoba; Research Institute in Oncology and Hematology; CancerCare Manitoba","funders":"CancerCare Manitoba Foundation; Biogen; Gilead Sciences; Leukemia and Lymphoma Society; BeiGene; Sanofi; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company","keywords":"Obinutuzumab; Tolerability; Chronic lymphocytic leukemia; Hematology; Ibrutinib; Lymphoma","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.002759296,0.001768374,0.01171123,0.001449259,0.0002508833,0.00007330979,0.0009387375,0.001475141,0.0002080432],"category_scores_gemma":[0.002331566,0.001371605,0.001021847,0.002956037,0.001331645,0.0001655624,0.001884859,0.0006110008,0.00004816516],"about_ca_system_candidate":true,"about_ca_system_consensus":true,"about_ca_system_score_codex":0.3464404,"about_ca_system_score_gemma":0.2814021,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.01267529,"about_ca_topic_score_gemma":0.002914135,"domain_scores_codex":[0.9888387,0.001267662,0.004578001,0.00257119,0.001095934,0.001648459],"domain_scores_gemma":[0.9920897,0.00284059,0.00157147,0.002476067,0.0003692325,0.0006528998],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"systematic_review","study_design_scores_codex":[0.0006363216,0.00008747378,0.00002237375,0.3777682,0.0002191831,0.001227523,0.00006952172,0.000003886077,0.000002219768,0.000218271,0.000384735,0.6193603],"study_design_scores_gemma":[0.05242419,0.002026047,0.0005938044,0.5441546,0.005109137,0.009419971,0.0000510775,0.006500337,0.00005441343,0.00018029,0.3771503,0.00233582],"study_design_candidate":"systematic_review","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.009158434,0.9752825,0.00001360355,0.00004757011,0.0002126263,0.009366184,0.0001245449,0.0001844501,0.005610105],"genre_scores_gemma":[0.00252963,0.9940836,0.0004945734,0.0002587032,0.0001483781,0.0009899371,0.00027662,0.0001432547,0.001075336],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.6170245,"threshold_uncertainty_score":0.9998211,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03306404265306265,"score_gpt":0.3343913292221242,"score_spread":0.3013272865690616,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}